Bioimpedance Spectroscopy for the Differential Diagnosis of Hyponatremia

Zonguldak Bulent Ecevit University58 enrolled

Overview

We aimed to investigate the role of bioimpedance spectroscopy for the diagnosis of hyponatremia

* Up to now, "Hyponatremia" differentially diagnosed by physical examination, plasma and urine osmolalities, Echocardiography and biochemical measurements. * The purpose of this study is to determine whether bioimpedance spectroscopy can be used for the detection of hypovolemia and hypervolemia for the differential diagnosis of hyponatremia.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hyponatremia

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Willing to participate in the study with written informed consent * Older than 18-years Exclusion Criteria: * The presence of pacemaker or defibrillator * Artificial joints, pin or amputation * Pregnancy or lactating.

Locations (1)

Bulent Ecevit University Hospital

Zonguldak, Turkey (Türkiye)

Outcomes

Primary Outcomes

Accuracy of volume status measured by bioimpedance spectroscopy

BIOIMPEDANCE SPECTROSCOPY: Overhydration (OH) measurement by Body Composition Monitor (Fresenius Medical Care) Negative values of "OH" indicating Hypovolemia and positive values for hypervolemia in hyponatremic patients.

Time frame: Six months

Secondary Outcomes

Laboratory data and echocardiography

LABORATORY MEASUREMENTS Hemoglobin, Hematocrit, White blood cell count Platelet count, Na, Potassium, Chlorur, Urea, Creatinine, Uric acid, Plasma osmolality, Urine osmolality, Alanine transaminase , Aspartate transaminase , Urine specific gravity, TREATMENT MODALITY 1. Diuretics 2. Intravenous hydration by isotonic saline ECHOCARDIOGRAPHY: Left ventricular end-diastolic diameter, Left ventricular end-systolic diameter, Ejection fraction(%), Left Atrium diameter, Aortic diameter, Right atrium diameter, Interventricular septum, Posterior wall thickness, Mitral insufficiency, Pulmonary insufficiency, Systolic pulmonary artery pressure, Tricuspid insufficiency

Time frame: 6 Months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.